Is tesamorelin a steroid? The answer is no. Tesamorelin is a peptide—a chain of amino acids—not an anabolic steroid. It isn't growth hormone itself, either. It is an analogue of growth-hormone-releasing hormone (GHRH), meaning it copies a natural signal that tells the pituitary gland to release the body's own growth hormone.
That distinction matters for side effects, medical use, and drug testing. Tesamorelin can affect a hormone pathway and still belong to a completely different chemical family from steroids.
Is tesamorelin a steroid? The chemistry says no
Tesamorelin is built from the same 44 amino acids as human GHRH, with a small modification that helps the molecule resist breakdown. The current Egrifta WR prescribing information describes it as a synthetic human growth-hormone-releasing factor analogue.
An anabolic-androgenic steroid is a testosterone-related hormone with a four-ring carbon structure. It acts mainly through the androgen receptor, a docking site inside cells that responds to testosterone-like signals. Tesamorelin has neither that structure nor that target.
Medicine also uses the word steroid for corticosteroids, drugs such as prednisone that copy adrenal hormones and calm inflammation. Tesamorelin isn't one of those, either.
| Compound type | What enters the body | Main target | Immediate job |
|---|---|---|---|
| Tesamorelin | A 44-amino-acid GHRH-like peptide | GHRH receptor on the pituitary | Signals release of the body's growth hormone |
| HGH | Growth hormone itself | Growth-hormone receptors in many tissues | Supplies the finished hormone |
| Anabolic steroid | A testosterone-related steroid molecule | Androgen receptor | Produces testosterone-like effects |
How tesamorelin reaches the growth-hormone pathway
The pituitary is a pea-sized gland beneath the brain that releases several hormones. Tesamorelin binds to GHRH receptors on its growth-hormone-producing cells. The gland then releases growth hormone in pulses, and that can raise IGF-1, a hormone that carries many of growth hormone's signals through the body.
A 12-month randomized trial in 404 adults described tesamorelin as GHRH(1–44) and measured a rise in IGF-1 along with its clinical outcomes (Falutz et al., Journal of Acquired Immune Deficiency Syndromes, 2010). That is evidence that the pathway was engaged. It does not turn the peptide into HGH or a steroid.
Tesamorelin, HGH, and sermorelin are related but different
Tesamorelin and HGH meet at the same pathway from opposite directions. HGH supplies growth hormone from outside the body. Tesamorelin sends the earlier message and depends on a working pituitary to respond.
Sermorelin is the closer relative. It is a shorter, 29-amino-acid piece of GHRH, while tesamorelin follows the full 44-amino-acid sequence with a stabilizing modification. Both signal the pituitary, but they aren't interchangeable. The neighboring guide on whether sermorelin is a steroid explains that molecule, while the tesamorelin product page covers the prescription route for this one.
Why WADA prohibits tesamorelin anyway
A place on a prohibited list is not a chemistry label. Sport regulators group substances by their potential biological effect as well as by what the molecules are made from.
The World Anti-Doping Agency's 2026 Prohibited List names tesamorelin under S2.2.4, growth-hormone-releasing factors. It is prohibited at all times, which WADA defines as both in and out of competition. Anabolic steroids sit in a separate section, S1.
For an athlete subject to testing, a prescription alone does not settle the matter. A Therapeutic Use Exemption, or TUE, is formal permission to use a prohibited treatment for a documented medical need. The athlete's anti-doping organization decides whether one is required and whether the application meets its rules.
The side effects are not the steroid side-effect pattern
Different chemistry does not mean no risk. Tesamorelin raises growth hormone and IGF-1, so its concerns follow that pathway. The brand label warns about elevated IGF-1, fluid retention, glucose intolerance or diabetes, allergic reactions, and injection-site reactions. In the first 26 weeks of its trials, injection-site reactions occurred in about 1 in 4 tesamorelin-treated participants and about 1 in 7 placebo-treated participants.
Anabolic steroids have a different risk pattern because they act through testosterone-like signaling. A peer-reviewed clinical review lists acne, high blood pressure, unhealthy cholesterol changes, liver injury, testosterone deficiency, erectile dysfunction, breast-tissue growth, and heart-muscle disease among the possible effects of nonmedical high-dose use (Bond, Smit, and de Ronde, Frontiers in Endocrinology, 2022).
Those lists should not be read as a claim that one drug class is simply safe and the other dangerous. Dose, health history, indication, and product quality all matter. The useful point is narrower: tesamorelin's known risks are not the classic androgen-related effects of anabolic steroids. For the broader comparison, see peptides versus steroids.
What changed in 2026—and what didn't
As of September 9, 2026, the day this article was written, a systematic review published July 31, 2026 pooled four randomized trials with 909 adults who had HIV-associated lipodystrophy, an abnormal distribution of body fat. It found growth-hormone-related side effects and said longer-term safety and durability still need more study (Ditta et al., Journal of the International Association of Providers of AIDS Care, 2026). The paper did not compare tesamorelin with anabolic steroids, and it did not change the molecule's classification.
A separate FDA warning letter dated August 24, 2026 identified specific products marketed online as tesamorelin and a tesamorelin/ipamorelin blend as unapproved new drugs. That action concerned those products and their marketing. It did not turn tesamorelin into a steroid or erase the branded drug's existing label.
The source of the vial therefore matters. A gray-market product can carry a familiar ingredient name without a prescriber, a dispensing pharmacy, a traceable label, or a clear path for reporting a problem. A prescribed compounded medication connects those pieces to a named patient.
Through Promise, tesamorelin is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The current Egrifta WR label covers reduction of excess abdominal fat in adults with HIV and lipodystrophy; it also says the brand is not indicated for weight-loss management because its effect on body weight is neutral.
Regulatory status isn't a marketing verdict. A licensed provider may still prescribe a compounded formulation; that decision is between you and your doctor. At Promise, a licensed provider reviews every request and not everyone qualifies.
The practical bottom line
For ordinary medical classification, tesamorelin is a GHRH analogue, not a steroid and not HGH. For tested sport, it is still a prohibited growth-hormone-releasing factor. For medical care, the exact product, reason for prescribing, glucose and IGF-1 history, and source all deserve separate attention.
If anti-doping rules apply, the right question is not whether the medication feels performance-related. It is whether the active ingredient appears on the current list and what the relevant organization requires before treatment begins.